StockDuty ← Dashboard Nov 06, 2026 08:37 AM ET
SignalCorporate

Biodesix expects $101M-$103M 2026 revenue while planning to exit 2026 with ~115 sales reps

Biodesix projects $101M–$103M 2026 revenue and ~115 sales reps exiting 2026.

What happened: Biodesix reported third quarter results and said it expects 2026 revenue of $101M to $103M while planning to exit 2026 with about 115 sales reps. Key numbers: Q3 total revenue grew 10%, diagnostic testing revenue rose 16%, test volumes grew 24%, gross margin was 81%. 2026 revenue guidance is $101M to $103M. About 115 sales reps targeted at 2026 exit. Why it matters: Management framed the quarter as continued meaningful progress, with diagnostic testing growth outpacing total revenue and gross margin described as remaining strong.
Biodesix reported third quarter results and said it expects 2026 revenue of $101M to $103M while planning to exit 2026 with about 115 sales reps.
Management framed the quarter as continued meaningful progress, with diagnostic testing growth outpacing total revenue and gross margin described as remaining strong.
Sources